Teresa Garcia-Lezana
Overview
Explore the profile of Teresa Garcia-Lezana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
927
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao B, Wang W, Li N, Garcia-Lezana T, Che C, Wang X, et al.
Talanta
. 2022 Jan;
241:123256.
PMID: 35085990
Small noncoding RNAs (snRNA) have been emerging as promising diagnostic biomarkers for detecting early stage cancer. Currently existing methods for snRNA detection, including northern blot, reverse transcription-polymerase chain reaction, microarrays...
2.
von Felden J, Garcia-Lezana T, Dogra N, Gonzalez-Kozlova E, Ahsen M, Craig A, et al.
Gut
. 2021 Jul;
PMID: 34321221
Objective: Surveillance tools for early cancer detection are suboptimal, including hepatocellular carcinoma (HCC), and biomarkers are urgently needed. Extracellular vesicles (EVs) have gained increasing scientific interest due to their involvement...
3.
Craig A, Garcia-Lezana T, Ruiz de Galarreta M, Villacorta-Martin C, Kozlova E, Martins-Filho S, et al.
PLoS Genet
. 2021 Jun;
17(6):e1009589.
PMID: 34166362
Cancer testis antigens (CTAs) are an extensive gene family with a unique expression pattern restricted to germ cells, but aberrantly reactivated in cancer tissues. Studies indicate that the expression (or...
4.
Garcia-Lezana T, Lopez-Canovas J, Villanueva A
Adv Cancer Res
. 2021 Feb;
149:63-101.
PMID: 33579428
Despite the recent introduction of new effective systemic agents, the survival of patients with hepatocellular carcinoma (HCC) at advanced stages remains dismal. This underscores the need for new therapies, which...
5.
Hernandez-Meza G, von Felden J, Gonzalez-Kozlova E, Garcia-Lezana T, Peix J, Portela A, et al.
Hepatology
. 2020 Nov;
74(1):183-199.
PMID: 33237575
Background And Aims: Mutations in TERT (telomerase reverse transcriptase) promoter are established gatekeepers in early hepatocarcinogenesis, but little is known about other molecular alterations driving this process. Epigenetic deregulation is...
6.
von Felden J, Craig A, Garcia-Lezana T, Labgaa I, Haber P, DAvola D, et al.
Oncogene
. 2020 Oct;
40(1):140-151.
PMID: 33097857
Little is known about the mutational landscape of advanced hepatocellular carcinoma (HCC), and predictive biomarkers of response to systemic therapies are lacking. We aimed to describe the mutational landscape of...
7.
von Felden J, Garcia-Lezana T, Schulze K, Losic B, Villanueva A
Gut
. 2020 Sep;
69(11):2025-2034.
PMID: 32883873
With increasing knowledge on molecular tumour information, precision oncology has revolutionised the medical field over the past years. Liquid biopsy entails the analysis of circulating tumour components, such as circulating...
8.
Barbera A, Raurell I, Garcia-Lezana T, Torres-Arauz M, Bravo M, Hide D, et al.
Liver Int
. 2020 Aug;
40(11):2732-2743.
PMID: 32770818
Background & Aims: Portal hypertension (PH) can be present in pre-cirrhotic stages, even in absence of fibrosis in non-alcoholic steatohepatitis (NASH) patients. Liver endothelial dysfunction (ED) has been shown as...
9.
Losic B, Craig A, Villacorta-Martin C, Martins-Filho S, Akers N, Chen X, et al.
Nat Commun
. 2020 Jan;
11(1):291.
PMID: 31941899
Clonal evolution of a tumor ecosystem depends on different selection pressures that are principally immune and treatment mediated. We integrate RNA-seq, DNA sequencing, TCR-seq and SNP array data across multiple...
10.
Craig A, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A
Nat Rev Gastroenterol Hepatol
. 2019 Dec;
17(3):139-152.
PMID: 31792430
Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, typically develops on the background of chronic liver disease and is an aggressive disease with dismal prognosis. Studies using...